SEC filing · 8-K

Biomarin Pharmaceutical Inc: Executive or director change

BioMarin Pharmaceutical appointed Dr. Robert Plenge to its Board of Directors and expanded the board to eleven members.

Filed September 14, 2026

Neutral news

What happened

On September 10, 2026, the Board of Directors increased its size from ten to eleven members and appointed Robert Plenge, M.D., Ph.D., as a director.

The full interpretation is in the app

Why it matters, the key numbers from the document and what to watch next: the full interpretation of every report is part of Pro.

Read the full interpretation

Read the original

Filing document on SEC.gov All documents of this filing

Back to Biomarin Pharmaceutical Inc

Summary generated automatically from the filing text and checked against it: every number above is printed in the document. It describes the filing and is not investment advice. Read the original before relying on it.